| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Diabetes Division (E.F., Y.M., M.M., R.A.D.), Department of Medicine, University of Texas Health Science Center, San Antonio, Texas 78229-3900; Metabolism Unit (E.F., A.G.), Department of Internal Medicine and Consiglio Nazionale delle Richerche Institute of Clinical Physiology, University of Pisa School of Medicine, 56126 Pisa, Italy; and Consiglio Nazionale delle Richerche Institute of Biomedical Engineering (A.M.), 35127 Padova, Italy
Address all correspondence and requests for reprints to: Ele Ferrannini, M.D., Department of Internal Medicine, Via Roma, 67, I-56100 Pisa, Italy. E-mail: ferranni{at}ifc.cnr.it.
The nature of the progressive ß-cell failure occurring as normal glucose tolerant (NGT) individuals progress to type 2 diabetes (T2DM) is incompletely understood. We measured insulin sensitivity (by a euglycemic insulin clamp) and insulin secretion rate (by deconvolution of plasma C-peptide levels during an oral glucose tolerance test) in 188 subjects [19 lean NGT (body mass index [BMI]
25 kg/m2), 42 obese NGT, 22 BMI-matched impaired glucose tolerance [IGT], and 105 BMI-matched T2DM]. Main determinants of ß-cell function on the oral glucose tolerance test were derived from a mathematical model featuring the following: 1) glucose concentration-insulin secretion dose response (glucose sensitivity), 2) a secretion component proportional to the derivative of plasma glucose concentration (rate sensitivity); and 3) a potentiation factor. When NGT and T2DM were subgrouped by 2-h plasma glucose concentrations, insulin secretion rate revealed an inverted U-shaped pattern, rising through NGT up to IGT and falling off thereafter. In contrast, ß-cell glucose sensitivity dropped in a monophasic, curvilinear fashion throughout the range of 2-h plasma glucose. Within the NGT range (2-h glucose of 4.17.7 mmol/liter), ß-cell glucose sensitivity declined by 5070% (P < 0.02). Insulin sensitivity decreased sharply in the transition from lean to obese NGT and then declined further in IGT and mild T2DM to level off in the higher three quartiles of diabetic hyperglycemia. In T2DM, defective ß-cell potentiation and rate sensitivity also emerged (P
0.05). In the whole data set, insulin sensitivity and the dynamic parameters of ß-cell function explained 89% of the variability of 2-h plasma glucose levels. The following conclusions were reached: 1) ß-cell glucose sensitivity falls already within the NGT range in association with rising 2-h plasma glucose concentrations, although absolute insulin secretion rates increase; and 2) throughout the glucose tolerance range, dynamic parameters of ß-cell function (glucose sensitivity, rate sensitivity, and potentiation) and insulin sensitivity are independent determinants of 2-h plasma glucose levels.
This article has been cited by other articles:
![]() |
M. Salehi, B. A. Aulinger, and D. A. D'Alessio Targeting {beta}-Cell Mass in Type 2 Diabetes: Promise and Limitations of New Drugs Based on Incretins Endocr. Rev., May 1, 2008; 29(3): 367 - 379. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. M. G. Cali', R. C. Bonadonna, M. Trombetta, R. Weiss, and S. Caprio Metabolic Abnormalities Underlying the Different Prediabetic Phenotypes in Obese Adolescents J. Clin. Endocrinol. Metab., May 1, 2008; 93(5): 1767 - 1773. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. M. Lalic, J. Maric, M. Svetel, A. Jotic, E. Stefanova, K. Lalic, N. Dragasevic, T. Milicic, L. Lukic, and V. S. Kostic Glucose Homeostasis in Huntington Disease: Abnormalities in Insulin Sensitivity and Early-Phase Insulin Secretion Arch Neurol, April 1, 2008; 65(4): 476 - 480. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Schernthaner and J. M. Morton Bariatric Surgery in Patients With Morbid Obesity and Type 2 Diabetes Diabetes Care, February 1, 2008; 31(Supplement_2): S297 - S302. [Full Text] [PDF] |
||||
![]() |
J. Movassat, D. Bailbe, C. Lubrano-Berthelier, F. Picarel-Blanchot, E. Bertin, J. Mourot, and B. Portha Follow-up of GK rats during prediabetes highlights increased insulin action and fat deposition despite low insulin secretion Am J Physiol Endocrinol Metab, January 1, 2008; 294(1): E168 - E175. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Rasouli, H. J. Spencer, A. A. Rashidi, and S. C. Elbein Impact of Family History of Diabetes and Ethnicity on -Cell Function in Obese, Glucose-Tolerant Individuals J. Clin. Endocrinol. Metab., December 1, 2007; 92(12): 4656 - 4663. [Abstract] [Full Text] [PDF] |
||||
![]() |
Authors/Task Force Members, L. Ryden, E. Standl, M. Bartnik, G. V. d. Berghe, J. Betteridge, M.-J. de Boer, F. Cosentino, B. Jonsson, M. Laakso, et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: full text: The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD) Eur. Heart J. Suppl., June 1, 2007; 9(suppl_C): C3 - C74. [Full Text] [PDF] |
||||
![]() |
T. A. Buchanan (How) Can We Prevent Type 2 Diabetes? Diabetes, June 1, 2007; 56(6): 1502 - 1507. [Full Text] [PDF] |
||||
![]() |
K. Cusi, S. Kashyap, A. Gastaldelli, M. Bajaj, and E. Cersosimo Effects on insulin secretion and insulin action of a 48-h reduction of plasma free fatty acids with acipimox in nondiabetic subjects genetically predisposed to type 2 diabetes Am J Physiol Endocrinol Metab, June 1, 2007; 292(6): E1775 - E1781. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. L. Wajchenberg {beta}-Cell Failure in Diabetes and Preservation by Clinical Treatment Endocr. Rev., April 1, 2007; 28(2): 187 - 218. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Camastra, M. Manco, A. Mari, A. V. Greco, S. Frascerra, G. Mingrone, and E. Ferrannini {beta}-Cell Function in Severely Obese Type 2 Diabetic Patients: Long-term effects of bariatric surgery Diabetes Care, April 1, 2007; 30(4): 1002 - 1004. [Full Text] [PDF] |
||||
![]() |
B. Ahren Insulin Secretion and Insulin Sensitivity in Relation to Fasting Glucose in Healthy Subjects Diabetes Care, March 1, 2007; 30(3): 644 - 648. [Abstract] [Full Text] [PDF] |
||||
![]() |
T H Schindler, A D Facta, J O Prior, J Cadenas, W A Hsueh, M J Quinones, and H R Schelbert Improvement in coronary vascular dysfunction produced with euglycaemic control in patients with type 2 diabetes Heart, March 1, 2007; 93(3): 345 - 349. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Gastaldelli, E. Ferrannini, Y. Miyazaki, M. Matsuda, A. Mari, and R. A. DeFronzo Thiazolidinediones improve beta-cell function in type 2 diabetic patients Am J Physiol Endocrinol Metab, March 1, 2007; 292(3): E871 - E883. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. T. Goh, T. M. Mason, N. Gupta, A. So, T. K. T. Lam, L. Lam, G. F. Lewis, A. Mari, and A. Giacca Lipid-induced beta-cell dysfunction in vivo in models of progressive beta-cell failure Am J Physiol Endocrinol Metab, February 1, 2007; 292(2): E549 - E560. [Abstract] [Full Text] [PDF] |
||||
![]() |
Authors/Task Force Members, L. Ryden, E. Standl, M. Bartnik, G. Van den Berghe, J. Betteridge, M.-J. de Boer, F. Cosentino, B. Jonsson, M. Laakso, et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary: The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD) Eur. Heart J., January 1, 2007; 28(1): 88 - 136. [Full Text] [PDF] |
||||
![]() |
G. Bock, C. Dalla Man, M. Campioni, E. Chittilapilly, R. Basu, G. Toffolo, C. Cobelli, and R. Rizza Pathogenesis of Pre-Diabetes: Mechanisms of Fasting and Postprandial Hyperglycemia in People With Impaired Fasting Glucose and/or Impaired Glucose Tolerance Diabetes, December 1, 2006; 55(12): 3536 - 3549. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Muscelli, A. Mari, A. Natali, B. D. Astiarraga, S. Camastra, S. Frascerra, J. J. Holst, and E. Ferrannini Impact of incretin hormones on beta-cell function in subjects with normal or impaired glucose tolerance Am J Physiol Endocrinol Metab, December 1, 2006; 291(6): E1144 - E1150. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. A. Abdul-Ghani, K. Williams, R. DeFronzo, and M. Stern Risk of Progression to Type 2 Diabetes Based on Relationship Between Postload Plasma Glucose and Fasting Plasma Glucose Diabetes Care, July 1, 2006; 29(7): 1613 - 1618. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Guidone, M. Manco, E. Valera-Mora, A. Iaconelli, D. Gniuli, A. Mari, G. Nanni, M. Castagneto, M. Calvani, and G. Mingrone Mechanisms of recovery from type 2 diabetes after malabsorptive bariatric surgery. Diabetes, July 1, 2006; 55(7): 2025 - 2031. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. A. Abdul-Ghani, D. Tripathy, and R. A. DeFronzo Contributions of {beta}-Cell Dysfunction and Insulin Resistance to the Pathogenesis of Impaired Glucose Tolerance and Impaired Fasting Glucose Diabetes Care, May 1, 2006; 29(5): 1130 - 1139. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. M. Dekker and B. Balkau Counterpoint: Impaired Fasting Glucose: The Case Against the New American Diabetes Association Guidelines Diabetes Care, May 1, 2006; 29(5): 1173 - 1175. [Full Text] [PDF] |
||||
![]() |
A. H. Xiang, C. Wang, R. K. Peters, E. Trigo, S. L. Kjos, and T. A. Buchanan Coordinate Changes in Plasma Glucose and Pancreatic {beta}-Cell Function in Latino Women at High Risk for Type 2 Diabetes. Diabetes, April 1, 2006; 55(4): 1074 - 1079. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. M. BERSTEIN, E. V. TSYRLINA, D. A. VASILYEV, T. E. POROSHINA, and R. G. KOVALENKO The Phenomenon of the Switching of Estrogen Effects and Joker Function of Glucose: Similarities and Relation to Age-Associated Pathology and Approaches to Correction Ann. N.Y. Acad. Sci., December 1, 2005; 1057(1): 235 - 246. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Camastra, M. Manco, A. Mari, S. Baldi, A. Gastaldelli, A. V. Greco, G. Mingrone, and E. Ferrannini {beta}-Cell Function in Morbidly Obese Subjects During Free Living: Long-Term Effects of Weight Loss Diabetes, August 1, 2005; 54(8): 2382 - 2389. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. Rathmann, B. Haastert, G. Giani, R. Holle, W. Koenig, C. Herder, and H. Lowel Critical Evaluation of Models to Identify Individuals With Insulin Resistance Diabetes Care, July 1, 2005; 28(7): 1833 - 1833. [Full Text] [PDF] |
||||
![]() |
A. Mari, A. Gastaldelli, J. E. Foley, R. E. Pratley, and E. Ferrannini {beta}-Cell Function in Mild Type 2 Diabetic Patients: Effects of 6-month glucose lowering with nateglinide Diabetes Care, May 1, 2005; 28(5): 1132 - 1138. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |